



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/216,242	12/18/98	LIPARI	J 6439.US.01

HM22/0327

STEVEN F WEINSTOCK  
ABBOTT LABORATORIES  
D 377 AP6D  
100 ABBOTT PARK ROAD  
ABBOTT PARK IL 60064-3500

EXAMINER

KISHORE, G

ART UNIT

PAPER NUMBER

1615

DATE MAILED: 03/27/00

This is a communication from the examiner in charge of your application.  
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

- ☐ Responsive to communication(s) filed on \_\_\_\_\_
- ☐ This action is FINAL.
- ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

- ☒ Claim(s) 1-20 is/are pending in the application.
- Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- ☒ Claim(s) 1-20 is/are rejected.
- ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- ☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.
- ☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- ☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been
- ☐ received.
- ☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_
- ☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

- ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- ☒ Notice of Reference Cited, PTO-892
- ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_
- ☐ Interview Summary, PTO-413
- ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☐ Notice of Informal Patent Application, PTO-152

- SEE OFFICE ACTION ON THE FOLLOWING PAGES -

Art Unit: :1615

### **DETAILED ACTION**

**The request for the correction of filing receipt dated 2-25-99 is acknowledged.**

**Applicant indicates the enclosure of PTOL-1449 in the IDS dated 3-8-99; but no 1449 is found in the file. The examiner requests the resubmission of 1449 and the copies of the references cited.**

#### ***Specification***

- 1. The disclosure is objected to because of the following informalities: The figures 1 and 2 in the specification should be canceled and submitted as separate Figures as separate sheets.**

**Appropriate correction is required.**

#### ***Claim Rejections - 35 U.S.C. § 112***

- 2. The following is a quotation of the first paragraph of 35 U.S.C. 112:**

**The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.**

- 3. Claims 1-20 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for fenofibrate as the drug and triglycerides as the solubilizer, does not reasonably provide enablement for generic 'lipid regulating agent' and structured lipid'. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention**

Art Unit: :1615

commensurate in scope with these claims. Instant specification lacks adequate disclosure as to what the lipid regulating agents and structured lipids could be used in practicing the invention. Broad claims must have broad basis of support in the specification; in the absence of such claims must be limited to fenofibrate and triglycerides.

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claims 1-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

It is unclear as to what applicants intend to convey by 'structured lipid' in claim 1.

Proper Markush format 'selected from the group consisting of' should be followed in claims 4, 7 and 20. Claim 7 recites only one component; the use of 'selected from' is improper.

It is unclear from claim 9 whether the lipid regulating agent is different from that in claim 1.

#### *Double Patenting*

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d

Art Unit: :1615

1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 1-20 provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-32 of copending Application No. 09/216,448. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant 'structured lipid' encompasses the species in the claims of said copending application.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

8. Claims 1-20 provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 09/216,247. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant 'structured lipid' encompasses the species in the claims of said copending application.

Art Unit: :1615

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

9. Claims 1-20 provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 3-8, 12, 14-20 of copending Application No. 09/215,831. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant 'structured lipid' encompasses the species in the claims of said copending application.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

*Claim Rejections - 35 U.S.C. § 102*

10. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

11. Claims 1-19 rejected under 35 U.S.C. 102(b) as being anticipated by Lacy (5,645,856).

Lacy discloses capsules containing emulsions of fenofibrate. The emulsions contain a triglyceride, polyglycerol esters of fatty acids and a cosolvent; the composition further

Art Unit: :1615

contains Capric/caprylic triglycerides such as Miglycol and Captex (note columns 4 and 5 and Example 6).

*Claim Rejections - 35 U.S.C. § 103*

12. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

13. Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lacy cited above.

Lacy does not teach all the lipid metabolism regulating agents. It is within the skill of the art to use any lipid regulating agent based on the guidance provided by Lacy with the expectation of obtaining similar results. It is unclear from Lacy whether the miglycols and Captex used correspond to instant claimed triglycerides. It is deemed to be within the skill of the art to select a proper triglyceride with the expectation of obtaining similar results from the teachings of Lacy. Lacy also does not specifically teach through examples the method of treatment of hyperlipidemia using an effective amount of the fenofibrate. Since the compound is a known lipid metabolism regulating agent, it is deemed obvious to one of ordinary skill in the art to use the formulations for the lipid regulating purposes.

Art Unit: :1615

**14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *G.S. Kishore* whose telephone number is (703) 308-2440.**

**The examiner can normally be reached on Monday-Thursday from 6:30 A.M. to 4:00 P.M. The examiner can also be reached on alternate Fridays.**

**If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, T.K. Page, can be reached on (703)308-2927. The fax phone number for this Group is (703)305-3592.**

**Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [thurman.page@uspto.gov].**

**All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.**

Application/Control Number: 09/216,242

Page 8

Art Unit: :1615

**Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703)308-1235.**



**Gollamudi S. Kishore, Ph. D**

**Primary Examiner**

**Group 1600**

*gsk*

**March 16, 2000**